Knockdown of UCA1 restrains cell proliferation and metastasis of diffuse large B‑cell lymphoma by counteracting miR‑331‑3p expression

Zhang, Minqing; Du, Yi; Shang, J.M.; Zhang, Dongqing; Dong, Xiaoqing; Chen, Hong

doi:10.3892/ol.2020.12300

Cited by 6 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Noncoding RNAs Target gene Function in human cancer metastasis LncRNA SNHG20 miR-495 Overexpression of lncRNA SNHG12 regulates tumor metastasis by modulating HER2 via miR-495 [ 21 ] HOTAIR miR-331-3p MiR-331-3p inhibited tumor metastasis by targeting MLLT10 in NSCLC [ 131 ]. Several lnc RNAs including UCA1 [ 132 ], MIAT [ 133 ] and XLOC_006390 [ 134 ] promoted cancer metastasis via regulating miR-331 in human cancers. LncRNA3037 miR-15a lncRNA3037 is down-regulated in tracheal tissue.…”

Section: Necroptosis and Cancer Metastasismentioning

confidence: 99%

Non-coding RNAs in necroptosis, pyroptosis and ferroptosis in cancer metastasis

et al. 2021

View full text Add to dashboard Cite

Distant metastasis is the main cause of death for cancer patients. Recently, the newly discovered programmed cell death includes necroptosis, pyroptosis, and ferroptosis, which possesses an important role in the process of tumor metastasis. At the same time, it is widely reported that non-coding RNA precisely regulates programmed death and tumor metastasis. In the present review, we summarize the function and role of necroptosis, pyrolysis, and ferroptosis involving in cancer metastasis, as well as the regulatory factors, including non-coding RNAs, of necroptosis, pyroptosis, and ferroptosis in the process of tumor metastasis.

show abstract

Section: Necroptosis and Cancer Metastasismentioning

confidence: 99%

Non-coding RNAs in necroptosis, pyroptosis and ferroptosis in cancer metastasis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Other lncRNAs with a diagnostic value and higher expression in patients with DLBCL include SBF2‐AS1, 39 NORAD, 40 NONHSAT078790 23 and NONHSAT102729. 23 LncRNAs with a prognostic value for DLBCL include SNHG12, 41 , 42 NEAT1, 43 , 44 , 45 LINC00857, 46 MALAT1, 47 , 48 HAGLROS, 49 PVT1, 50 PCAT1 51 and UCA1, 52 which were upregulated, and LincRNA‐p21, 53 which was downregulated. Most of the lncRNAs mentioned above (diagnostic/prognostic/both) are suggested to be therapeutic targets for patients with DLBCL.…”

Section: Resultsmentioning

confidence: 99%

Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review

Khanmohammadi,

Fallahtafti

2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Cancer initiation and progression have been associated with dysregulated long non-coding RNA (lncRNA) expression. However, the lncRNA expression profile in aggressive B-cell non-Hodgkin lymphoma (NHL) has not been comprehensively characterized. This systematic review aims to evaluate the role of lncRNAs as a biomarker to investigate their future potential in the diagnosis, real-time measurement of response to therapy and prognosis in aggressive B-cell NHL. We searched PubMed, Web of Science, Embase and Scopus databases using the keywords "long non-coding RNA", "Diffuse large B-cell lymphoma", "Burkitt's lymphoma" and "Mantle cell lymphoma". We included studies on human subjects that measured the level of lncRNAs in samples from patients with aggressive B-cell NHL. We screened 608 papers, and 51 papers were included. The most studied aggressive B-cell NHL was diffuse large B-cell lymphoma (DLBCL). At least 79 lncRNAs were involved in the pathogenesis of aggressive B-cell NHL. Targeting lncRNAs could affect cell proliferation, viability, apoptosis, migration and invasion in aggressive B-cell NHL cell lines. Dysregulation of lncRNAs had prognostic (e.g. overall survival) and diagnostic values in patients with DLBCL, Burkitt's lymphoma (BL), or mantle cell lymphoma (MCL). Furthermore, dysregulation of lncRNAs was associated with response to treatments, such as CHOP-like chemotherapy regimens, in these patients. LncRNAs could be promising biomarkers for the diagnosis, prognosis and response to therapy in patients with aggressive B-cell NHL. Additionally, lncRNAs could be potential therapeutic targets for patients with aggressive B-cell NHL like DLBCL, MCL or BL.

show abstract

“…In that case, UCA1’s knockdown results in a drug sensitivity restoration and is expected to be a suitable diagnostic marker [ 61 ]. UCA1’s knockdown was revealed to restrain cell proliferation, migration, and invasion in large B-cell lymphoma by suppressing miR-331-3p expression [ 62 ]. It was also suggested as a possible medicinal target and biomarker for large B-cell lymphoma.…”

Section: Synthetic Non-coding Rnas As Therapeutic Agentsmentioning

confidence: 99%

Antisense and Functional Nucleic Acids in Rational Drug Development

Penchovsky,

Georgieva,

Dyakova

et al. 2024

Antibiotics

View full text Add to dashboard Cite

This review is focused on antisense and functional nucleic acid used for completely rational drug design and drug target assessment, aiming to reduce the time and money spent and increase the successful rate of drug development. Nucleic acids have unique properties that play two essential roles in drug development as drug targets and as drugs. Drug targets can be messenger, ribosomal, non-coding RNAs, ribozymes, riboswitches, and other RNAs. Furthermore, various antisense and functional nucleic acids can be valuable tools in drug discovery. Many mechanisms for RNA-based control of gene expression in both pro-and-eukaryotes and engineering approaches open new avenues for drug discovery with a critical role. This review discusses the design principles, applications, and prospects of antisense and functional nucleic acids in drug delivery and design. Such nucleic acids include antisense oligonucleotides, synthetic ribozymes, and siRNAs, which can be employed for rational antibacterial drug development that can be very efficient. An important feature of antisense and functional nucleic acids is the possibility of using rational design methods for drug development. This review aims to popularize these novel approaches to benefit the drug industry and patients.

show abstract

Knockdown of UCA1 restrains cell proliferation and metastasis of diffuse large B‑cell lymphoma by counteracting miR‑331‑3p expression

Cited by 6 publications

References 35 publications

Non-coding RNAs in necroptosis, pyroptosis and ferroptosis in cancer metastasis

Non-coding RNAs in necroptosis, pyroptosis and ferroptosis in cancer metastasis

Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review

Antisense and Functional Nucleic Acids in Rational Drug Development

Contact Info

Product

Resources

About